Lonnel Coats
CIK: 0001612528
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Oct 19, 2026MLYS
Mineralys Therapeutics, Inc.
Award(A)Direct12.4K shares- - Jun 9, 2026RLAY
Relay Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
32.9K shares- - Nov 4, 2025RLAY
Relay Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
207.9K shares- - Jul 25, 2025VERV
Verve Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
42.2K shares- - Jul 25, 2025VERV
Verve Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
136.1K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Disposition(D)Direct6.1K shares- - Jun 18, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct3.9K shares at avg. $12812.00$50.0M - Jun 5, 2025VERV
Verve Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
42.2K shares- - Nov 21, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct9.8K shares at avg. $94.87$932K - Nov 20, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct213 shares at avg. $94.99$20K - Nov 20, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct5.3K shares at avg. $94.24$498K - Nov 20, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct4.5K shares at avg. $93.15$419K - Nov 20, 2024BPMC
Blueprint Medicines Corp
Exercise(M)Direct1.3K shares at avg. $76.24$100K - Nov 20, 2024BPMC
Blueprint Medicines Corp
Exercise(M)Direct7.5K shares at avg. $69.79$523K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 19, 2026 |  MLYS Mineralys Therapeutics, Inc. | Award(A) | 12,400 | - | $0 | Direct |
| Jun 9, 2026 |  RLAY Relay Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 32,947 | - | - | Direct |
| Nov 4, 2025 | RLAY Relay Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 207,931 | - | - | Direct |
| Jul 25, 2025 |  VERV Verve Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 42,200 | - | - | Direct |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 136,139 | - | - | Direct |
| Jul 17, 2025 |  BPMC Blueprint Medicines Corp | Disposition(D) | 6,144 | - | - | Direct |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | Award(A) | 3,902 | $12812.00 | $49,992,424 | Direct |
| Jun 5, 2025 | VERV Verve Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 42,200 | - | - | Direct |
| Nov 21, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 9,824 | $94.87 | $932,003 | Direct |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 213 | $94.99 | $20,233 | Direct |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 5,287 | $94.24 | $498,247 | Direct |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 4,500 | $93.15 | $419,175 | Direct |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | Exercise(M) | 1,312 | $76.24 | $100,027 | Direct |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | Exercise(M) | 7,500 | $69.79 | $523,425 | Direct |
1-14 of 14 transactions
About COATS LONNEL
COATS LONNEL (SEC CIK 0001612528) files insider reports with the SEC as Director of Mineralys Therapeutics, Inc. (MLYS), Director of Relay Therapeutics, Inc. (RLAY) and Director of Verve Therapeutics, Inc. (VERV). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by COATS LONNEL (2 Form 3, 8 Form 4), filed between Nov 22, 2024 and Oct 20, 2026. Those filings report 14 transactions, from Nov 20, 2024 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on COATS LONNEL's filings is in RADNOR, PA.
Recent filings by COATS LONNEL
- Oct 19, 2026: Grant or award of MLYS shares (Form 4, code A).
- Jun 9, 2026: Grant or award of RLAY derivative securities (Form 4, code A).
- Nov 4, 2025: Grant or award of RLAY derivative securities (Form 4, code A).
- Jul 25, 2025: Disposition to issuer transactions of VERV derivative securities (2 lines, Form 4, code D).
- Jul 17, 2025: Disposition to issuer transaction of BPMC shares (Form 4, code D).
Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)
- Peterson Kristine, Director
- Congleton Jon, Chief Executive Officer
- Slingsby Brian Taylor, Director
- Warren Eric, Chief Commercial Officer
- Karydas Daphne, Director
- Ferguson James J. III, Chief Medical Officer